2 Jul 2026Open access
Comparing tumour site and overall survival in colon v. rectal cancer in a longitudinal cohort study in Johannesburg, South AfricaPublisher siteSouth African Medical Journal, Colorectal Cancer Screening and Detection
Active, last published 2026
In colorectal cancer treatments and studies
Paul
Ruff
Scholar“Research focused on Colorectal Cancer Treatments and Studies and adjacent fields.”
University of the Witwatersrand
South Africa42
H-index
24.4k
Citations
Paul has not officially claimed their profile. If you are Paul, claim it free.
Claim Your Profile
Pioneer
LOCKED
Pathfinder
LOCKED
Scholar
EARNED
Innovator
LOCKED
Inventor
LOCKED
Catalyst
LOCKED
Expert
UPGRADE
01 · About the work
What I study
aul Ruff is a researcher working on Colorectal Cancer Treatments and Studies. A fuller summary will appear once they update their profile.
02 · Reach
Publication output and reach
Paul's work has been cited 24,414 times across 2 active years. Bars show publications per year; the line shows cumulative citation totals across publications first appearing in each year.
03 · Research focus
Topics
Colorectal Cancer Treatments and Studies×68Cancer Genomics and Diagnostics×41Viral-associated cancers and disorders×38Global Cancer Incidence and Screening×33Genetic factors in colorectal cancer×31
04 · Where I am
Affiliations
Affiliation on published researchUniversity of the Witwatersrand, South AfricaDrawn from the institution listed on this researcher’s published work.
Research themes (UN SDGs)
05 · Selected work
Recent publications
15 works20 Nov 2024Open access6cites
The association of HIV status with triple-negative breast cancer in patients with breast cancer in South Africa: a cross-sectional analysis of case-only data from a prospective cohort studyPublisher siteThe Lancet Global Health, Viral-associated cancers and disorders
19 Nov 2024Open access
Population pharmacokinetic modeling of tamoxifen and its active metabolite endoxifen in healthy volunteers of African ancestry genotyped for CYP2B6, CYP2C9, CYP2C19, CYP2D6, CYP3A4 and CYP3A5.Publisher site12 Nov 2024Open access4cites
Pembrolizumab 400 mg every 6 weeks as first-line therapy for advanced melanoma (KEYNOTE-555): Results from cohort B of an open-label, phase 1 studyPublisher sitePLoS ONE, Cancer Immunotherapy and Biomarkers
1 Oct 2024Open access
SAHR 2023: Complete editionPublisher siteSouth African Health Review
1 Oct 2024Open access
Introduction: Foreword, Contents, AcknowledgementsPublisher siteSouth African Health Review
1 Oct 2024Open access
SAHR 2023: At a glancePublisher siteSouth African Health Review, Medical Imaging Techniques and Applications
1 Oct 2024Open access
EditorialPublisher siteSouth African Health Review
Expert Academic Profiles go further
Citation trend analytics, exportable publication records, and direct enquiry routing from industry and funders.
Are you Paul?
Claim it to verify your details, connect with industry partners, and explore Fractional Domain Expert opportunities through MARATTO™.
African researchers are full of potential that too often goes unrecognised. Your MARATTO™ profile gives your work the commercial pathway it deserves.
Claim Your Profile
Free to claim · takes a minute to verify it’s you